# Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

> **NCT00096200** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT00096200
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2011-04-21
- **Final completion:** 2011-08
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096200, "Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00096200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*